Stocks To Buy Now

Blog


DGE 3rd Diversity in Clinical Trials Invites Pharmaceutical Professionals for Enlightening Discussions

DGE invites life science professionals to attend the 3rd Diversity In Clinical Trials Conference being held on May 15-16, 2024 at the Inn at Penn Philadelphia. The conference offers an valuable forum for meaningful interactions to understand the intricacies of and benefits of pursuing diverse enrollment in clinical studies.

The event is hosted by Dynamic Global Events (“DGE”), a global leader in organizing B2B events. The global event company caters to the dynamic informational and networking needs of the pharma, biotech, medical devices, and all healthcare industries.

New insights and successful strategies are pivotal for better clinical trial results. Pharma colleagues gather for a focused approach towards diversity, equity, and inclusion (DEI) for clinical trials. Having a complete understanding of the complexities and challenges of diverse participation in clinical trials will help organizations make the necessary changes in their planning and execution.

The event will be attended by a diverse group of industry veterans who will share their experience and views on improving diversity in organizations. The well-rounded agenda of the conference explores all issues and challenges of diverse enrolment in clinical trials.

The conference agenda includes:

  • Examining the past and present issues of DCT, the measures taken to solve these issues, and ways of improvisation for future achievements
  • Understanding the pivotal role of DCT in the life sciences industry for developing the most effective treatments for patients
  • A great learning session offering tips to avoid repeating mistakes and discussing new avenues for improvement and development
  • An important discussion on Digital Accessibility for Clinical Trial Diversity

After the registration, the event starts with the chairperson’s opening remarks. This is followed by speaker sessions, interaction, group discussions and networking among the attendees of the conference.

To learn more please visit https://ibn.fm/EBGQd.

From Our Blog

Nutriband Inc. (NASDAQ: NTRB) Innovating Abuse-Deterrent Drug Delivery in a Shifting Opioid Landscape

May 9, 2025

A Market Demanding Safer Opioid Solutions The opioid crisis remains a critical public health challenge in the U.S. and globally, prompting a series of new regulatory measures designed to improve safety and reduce misuse. In early 2025, the FDA approved Journavx (suzetrigine), a first-in-class non-opioid painkiller offering patients safer alternatives to opioids. Additionally, opioid manufacturers […]

Rotate your device 90° to view site.